The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis

Abstract

The safety profile of interleukin-1 receptor antagonist (anakinra) has been studied with randomised, placebo-controlled trials involving 2932 patients affected by rheumatoid arthritis. The most frequently reported adverse events were represented by injection site reactions (71%) and headache (13.6%). No statistically significant difference in the incidence of infections was observed among the patients treated with the interleukin-1 receptor antagonist and the patients receiving placebo. In particular, the incidence of serious infections was 1,8% in rheumatoid arthritis patients on anakinra therapy and 0,7% in patients on placebo. The reported serious infections consisted of pneumonia, cellulitis, bone and joint infections, bursitis. No case of opportunistic infections or tubercolosis was observed. The results of clinical studies suggest that anakinra is a new well-tolerated drug for the treatment of patients affected by rheumatoid arthritis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 448

  • PDF: 618
How to Cite
Riente, L. (1). The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis. Reumatismo, 56(1s), 74-79. https://doi.org/10.4081/reumatismo.2004.1s.74